- Home
- GAME vs KALA Comparison
GAME vs KALA Comparison
Compare GAME & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- KALA
- Stock Information
- Founded
- GAME 2011
- KALA 2009
- Country
- GAME United States
- KALA United States
- Employees
- GAME N/A
- KALA N/A
- Industry
- GAME
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- KALA Health Care
- Exchange
- GAME Nasdaq
- KALA Nasdaq
- Market Cap
- GAME 25.8M
- KALA 27.3M
- IPO Year
- GAME 2009
- KALA 2017
- Fundamental
- Price
- GAME $0.90
- KALA $6.64
- Analyst Decision
- GAME Strong Buy
- KALA Strong Buy
- Analyst Count
- GAME 3
- KALA 2
- Target Price
- GAME $3.67
- KALA $15.00
- AVG Volume (30 Days)
- GAME 297.3K
- KALA 108.1K
- Earning Date
- GAME 04-15-2025
- KALA 03-28-2025
- Dividend Yield
- GAME N/A
- KALA N/A
- EPS Growth
- GAME N/A
- KALA N/A
- EPS
- GAME N/A
- KALA N/A
- Revenue
- GAME $99,072,646.00
- KALA N/A
- Revenue This Year
- GAME $102.01
- KALA N/A
- Revenue Next Year
- GAME $17.88
- KALA N/A
- P/E Ratio
- GAME N/A
- KALA N/A
- Revenue Growth
- GAME 210.51
- KALA N/A
- 52 Week Low
- GAME $0.65
- KALA $4.21
- 52 Week High
- GAME $2.25
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- GAME 54.66
- KALA 39.29
- Support Level
- GAME $0.84
- KALA $6.50
- Resistance Level
- GAME $0.95
- KALA $8.65
- Average True Range (ATR)
- GAME 0.06
- KALA 0.90
- MACD
- GAME 0.00
- KALA -0.43
- Stochastic Oscillator
- GAME 62.69
- KALA 2.98
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.